Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins.
about
Putative Role of Red Wine Polyphenols against Brain Pathology in Alzheimer's and Parkinson's DiseaseThe Role of Amyloid-β Oligomers in Toxicity, Propagation, and ImmunotherapyRepA-WH1, the agent of an amyloid proteinopathy in bacteria, builds oligomeric pores through lipid vesicles.An ER-directed gelsolin nanobody targets the first step in amyloid formation in a gelsolin amyloidosis mouse modelUnraveling Comparative Anti-Amyloidogenic Behavior of Pyrazinamide and D-Cycloserine: A Mechanistic Biophysical InsightA scFv antibody targeting common oligomeric epitope has potential for treating several amyloidoses.Reactive γ-ketoaldehydes promote protein misfolding and preamyloid oligomer formation in rapidly-activated atrial cells.Differential effects on light chain amyloid formation depend on mutations and type of glycosaminoglycansHypertension is associated with preamyloid oligomers in human atrium: a missing link in atrial pathophysiology?A new mechanism links preamyloid oligomer formation in the myocyte stress response associated with atrial fibrillation.A native interactor scaffolds and stabilizes toxic ATAXIN-1 oligomers in SCA1.Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseasesTau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimer's Disease and Other Tauopathies.Detection of TDP-43 oligomers in frontotemporal lobar degeneration-TDP.The Biological Function of the Prion Protein: A Cell Surface Scaffold of Signaling ModulesThe interrelationship of proteasome impairment and oligomeric intermediates in neurodegeneration.Eukaryotic aggresomes: from a model of conformational diseases to an emerging type of immobilized biocatalyzers.Natural product-based amyloid inhibitors.Exploring Anti-Prion Glyco-Based and Aromatic Scaffolds: A Chemical Strategy for the Quality of Life.β-Hairpin mimics containing a piperidine-pyrrolidine scaffold modulate the β-amyloid aggregation process preserving the monomer species.Self-Assembled Cyclic d,l-α-Peptides as Generic Conformational Inhibitors of the α-Synuclein Aggregation and Toxicity: In Vitro and Mechanistic Studies.Non-Fibrillar Oligomeric Amyloid-β within Synapses.Amylin in Alzheimer's disease: Pathological peptide or potential treatment?Direct observation of oligomerization by single molecule fluorescence reveals a multi-step aggregation mechanism for the yeast prion protein Ure2.Serum amyloid A forms stable oligomers that disrupt vesicles at lysosomal pH and contribute to the pathogenesis of reactive amyloidosis.Pharmacological activation of autophagy favors the clearing of intracellular aggregates of misfolded prion protein peptide to prevent neuronal death.Resveratrol reduces amyloid-beta (Aβ₁₋₄₂)-induced paralysis through targeting proteostasis in an Alzheimer model of Caenorhabditis elegans.Blood-Based Oligomeric and Other Protein Variant Biomarkers to Facilitate Pre-Symptomatic Diagnosis and Staging of Alzheimer's Disease.Transthyretin Mimetics as Anti-β-Amyloid Agents: A comparison of peptide and protein approaches.A common mechanism of proteasome impairment by neurodegenerative disease-associated oligomers.Recent developments in solid lipid nanoparticle and surface-modified solid lipid nanoparticle delivery systems for oral delivery of phyto-bioactive compounds in various chronic diseases.
P2860
Q26738450-3F1A0ED7-851F-440F-96EF-A9E451AA2C15Q26747107-CE179415-5DEB-4DCE-B8E5-E09CEB094475Q27332087-32A36AAB-9AF9-4CFB-990D-C92FA6E64D64Q27697593-B14DF657-1F66-48F5-93F8-1F58C9C24533Q28547536-BB6961C0-F4FD-4671-A486-EA13EE86DD0CQ30827953-30396DF1-4DA2-440B-9F50-F9BE58365181Q34995740-DB753F81-F860-4428-9459-1EB15D1D0A39Q35103966-218CD359-717F-4B41-B72B-6A0DAEE7FFD0Q35115100-E7EFCCDC-399C-4EA1-A257-D88A51BC0EFDQ35137541-91B52E30-2DDF-4DE7-9B50-7E5CB1C62A50Q35715535-C99D7043-7A14-476B-BF57-68A22C71F7C2Q36479597-850B845E-C852-40C7-A0FD-B28379327CDBQ36558485-A5BFE93B-93A3-42A0-A109-C28F95FEB9CBQ36769877-B95BB43E-AA9D-4888-8264-B04F85C2ACB2Q37710410-12A8C788-A749-4E3C-9F97-9118346EAFA6Q38520167-82FE7F58-FDE4-4305-A890-DF49EE3D47CEQ38622861-F0197203-781A-4AC2-ABF2-0C69D16A6AB0Q38733078-590AFD6B-AE91-4E57-A0B1-9139204988FBQ39326827-8DE8DB99-5455-4C19-802A-7C252345054AQ42314973-0FD721EB-901C-4296-B9E9-EF3B9CBC4A34Q46500132-7A00D66E-1C94-4A41-8C36-A7D263588BDDQ46538110-9D7ABBE7-B3B6-455B-ABBE-78EA7FF693D6Q47322028-2F1F8F2D-BC7E-4688-B925-5F304B14BBF0Q47826829-A1D8B33A-FEB1-4D1F-93E5-EB718FC6DE5DQ48028286-513DB1B1-FE14-4B32-8EFD-9893B1AFD51EQ48507581-D82BB52C-87C7-433D-B556-C58A99C90195Q50448610-772B308A-F35A-440A-AE5F-E888A7144EE2Q50753131-21DB6CBF-0DE0-4491-9382-D22EF17E32E7Q51735672-0C1176DD-97F4-4557-8C80-62D62BCFCEDDQ52653236-7A40850E-A10B-4C41-AC9D-84001FFCB919Q55013574-39570CA1-E25F-4B88-BB72-D8B97780621A
P2860
Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Therapeutic approaches against ...... ltiple amyloidogenic proteins.
@en
type
label
Therapeutic approaches against ...... ltiple amyloidogenic proteins.
@en
prefLabel
Therapeutic approaches against ...... ltiple amyloidogenic proteins.
@en
P1476
Therapeutic approaches against ...... ultiple amyloidogenic proteins
@en
P2093
Marcos J Guerrero-Muñoz
Rakez Kayed
P304
P356
10.1016/J.BCP.2013.12.023
P407
P577
2014-01-07T00:00:00Z